Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-03Estimated
Enrollment · participants620Estimated
Source updated2026-11-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.